Article Information
History
- December 3, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Guy de Bruyn, MD*,1,
- Joyce Wang, MS2,
- Annie Purvis, MSPH3,
- Martin Sanchez Ruiz, MD4,
- Haritha Adhikarla, PhD1,
- Saad Alvi, MD5,
- Matthew I Bonaparte, PhD1,
- Daniel Brune, MD6,
- Agustin Bueso, MD7,
- Richard M Canter, MS1,
- Maria Angeles Ceregido, PhD8,
- Sachin Deshmukh, MD9,
- David Diemert, MD10,
- Adam Finn, MD11,
- Remi Forrat, MD12,
- Bo Fu, PhD1,
- Julie Gallais, MS12,
- Paul Griffin, MBBS13,
- Marie-Helene Grillet, MD14,
- Owen Haney, PharmD1,
- Jeffrey A Henderson, MD15,
- Marguerite Koutsoukos, MS8,
- Odile Launay, MD16,
- Federico Martinon Torres, MD17,
- Roger Masotti, MS1,
- Nelson L Michael, MD18,
- Juliana Park, MD19,
- Doris M Rivera M, MD20,
- Natalya Romanyak, PharmD1,
- Chris Rook, MB21,
- Lode Schuerman, MD8,
- Lawrence D Sher, MD22,
- Fernanda Tavares-Da-Silva, MD8,†,
- Ashley Whittington, MD23,
- Roman M Chicz, PhD3,
- Sanjay Gurunathan, MD1,
- Stephen Savarino, MD1,†,
- Saranya Sridhar, DPhil24 and
- the VAT00002 booster cohorts study team‡
- 1Sanofi, Swiftwater, PA, USA
- 2Sanofi, Chengdu, China
- 3Sanofi, Cambridge, MA, USA
- 4Sanofi, Paris, France
- 5Chicago Clinical Research Institute, IL, USA
- 6Optimal Research, Peoria, IL, USA
- 7Demedica, San Pedro Sula, Honduras
- 8GSK, Wavre, Belgium
- 9Griffith University, Australia
- 10School of Medicine and Health Sciences, George Washington University, Washington, DC, USA
- 11Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
- 12Sanofi, Marcy l’Etoile, France
- 13Mater Health, Brisbane, Queensland, Australia. The University of Queensland, Brisbane, Queensland, Australia
- 14Sanofi, Lyon, France
- 15Black Hills Center for American Indian Health, SD, USA
- 16Université Paris Cité; Inserm, F-CRIN I REIVAC, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
- 17Pediatrics Department, Translational Pediatrics and Infectious Diseases Section, Santiago de Compostela, Spain; Genetics- Vaccines- Infectious Diseases and Pediatrics research group GENVIP, Instituto de Investigación Sanitaria de Santiago (IDIS), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- 18Walter Reed Army Institute of Research, Silver Spring, MD, USA
- 19Sanofi, Sydney, Australia
- 20INVERIME S.A, Tegucigalpa, Honduras
- 21Cmax, Adelaide, Australia
- 22Peninsula Research Associates, Rolling Hills Estates, CA, USA
- 23London North West University Healthcare NHS Trust, London, UK
- 24Sanofi, Reading, UK
- ↵*Corresponding Author:
Guy de Bruyn, Sanofi, Swiftwater, PA, USA, Guy.DeBruyn{at}sanofi.com; Tel: +15709725671